Investment Summary

Athyrium Capital Management Invests In MedPro Safety Products

On February 28, 2012, asset manager Athyrium Capital Management invested in medical products company MedPro Safety Products

Investment Highlights
  • This is Athyrium Capital Management’s 1st transaction in the Medical Products sector.
  • This is Athyrium Capital Management’s 3rd transaction in the United States.
  • This is Athyrium Capital Management’s 1st transaction in Kentucky.

Investment Summary
Date 2012-02-28
Target MedPro Safety Products
Sector Medical Products
Investor(s) Athyrium Capital Management
Deal Type Growth Capital

Target

MedPro Safety Products

Lexington, Kentucky, United States
MedPro Safety Products develops innovative medication delivery products with proprietary passive needle stick prevention technology that protects healthcare workers and increases patient safety across the continuum of care. MedPro Safety Products is based in Lexington, Kentucky.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Investor(S) 1

Investor

Athyrium Capital Management

Investor Investor Investor Investor Investor

Category Asset Manager
Founded 2008
PE ASSETS 3.7B USD
Size Large
Type Sector Focused
DESCRIPTION

Athyrium Capital Management is a large asset manager focused on the healthcare sector. Athyrium invests in a wide range of financial instruments including royalties, structured credit, and equities as well as select special situations. Athyrium Capital was established in 2008 and is headquartered in New York City.

DEAL STATS #
Overall 3 of 44
Sector (Medical Products) 1 of 6
Type (Growth Capital) 1 of 10
State (Kentucky) 1 of 2
Country (United States) 3 of 39
Year (2012) 1 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2011-01-01 Alcresta Therapeutics

Newton, Massachusetts, United States

Alcresta Therapeutics is a specialty pharmaceutical company focusing on discovering and developing a new generation of enzyme-based products that improve digestion and absorption of important nutrients. The company's lead program is a point-of-care, enzyme-based product that improves the bioavailability of long-chain fatty acids (such as DHA, EPA, and AA) for patients with impaired pancreatic output. Compromised pancreatic function is a complication of many diseases such as cystic fibrosis, chronic pancreatitis, and cancer as well as developmental immaturity, and Alcresta's products are aimed at meeting the nutritional needs of these patients. Alcresta Therapeutics was formed in 2011 and is based in Newton, Massachusetts.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2012-12-10 Verenium

San Diego, California, United States

Verenium is a biotechnology company based in San Diego, California.

Buy -
Mergr

Product

Company

Legal